Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Denton

Showing results (301-310 of 484) with videos related to

Pageof 49
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|June 9, 2016
Brief Report: Anti-Eukaryotic Initiation Factor 2B Autoantibodies Are Associated With Interstitial Lung Disease in Patients With Systemic SclerosisZoe E Betteridge, Felix Woodhead, Hui Lu, et al.
Annals of the Rheumatic Diseases|February 10, 2026
Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosisMaithri Aspari, Voon Ong, Klaus Søndergaard, et al.
Experimental Dermatology|May 23, 2014
SMAD inhibition attenuates epithelial to mesenchymal transition by primary keratinocytes in vitroDonal O'Kane, Megan V Jackson, Adrien Kissenpfennig, et al.
RMD Open|February 16, 2023
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progressionDinesh Khanna, Toby M Maher, Elizabeth R Volkmann, et al.
Arthritis Research & Therapy|June 1, 2022
Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trialEdward P Stern, Lauren V Host, Ivy Wanjiku, et al.
Arthritis Research & Therapy|December 10, 2025
A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trialStefano Rodolfi, Kristina Clark, Bahja Ahmed Abdi, et al.
The International Journal of Biochemistry & Cell Biology|March 4, 2021
Selective deletion of connective tissue growth factor attenuates experimentally-induced pulmonary fibrosis and pulmonary arterial hypertensionAngela Y Y Tam, Amy L Horwell, Sarah L Trinder, et al.
Arthritis and Rheumatism|April 3, 2008
Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse modelRachel K Hoyles, Korsa Khan, Xu Shiwen, et al.
European Heart Journal. Cardiovascular Imaging|August 19, 2024
Prognostic utility of exercise cardiovascular magnetic resonance in patients with systemic sclerosis-associated pulmonary arterial hypertensionJames T Brown, Ruta Virsinskaite, Tushar Kotecha, et al.
Journal of Scleroderma and Related Disorders|June 24, 2024
Attitudes and barriers to pulmonary arterial hypertension screening in systemic sclerosis patients: A survey of UK-based rheumatologistsMaría Paula Álvarez-Hernández, Yannick Allanore, Ivo Andrade, et al.
Pageof 49

Showing results (301-310 of 484) with videos related to

Sort By:
Pageof 49
Arthritis & Rheumatology (Hoboken, N.J.)|June 9, 2016
Brief Report: Anti-Eukaryotic Initiation Factor 2B Autoantibodies Are Associated With Interstitial Lung Disease in Patients With Systemic SclerosisZoe E Betteridge, Felix Woodhead, Hui Lu, et al.
Annals of the Rheumatic Diseases|February 10, 2026
Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosisMaithri Aspari, Voon Ong, Klaus Søndergaard, et al.
Experimental Dermatology|May 23, 2014
SMAD inhibition attenuates epithelial to mesenchymal transition by primary keratinocytes in vitroDonal O'Kane, Megan V Jackson, Adrien Kissenpfennig, et al.
RMD Open|February 16, 2023
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progressionDinesh Khanna, Toby M Maher, Elizabeth R Volkmann, et al.
Arthritis Research & Therapy|June 1, 2022
Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trialEdward P Stern, Lauren V Host, Ivy Wanjiku, et al.
Arthritis Research & Therapy|December 10, 2025
A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trialStefano Rodolfi, Kristina Clark, Bahja Ahmed Abdi, et al.
The International Journal of Biochemistry & Cell Biology|March 4, 2021
Selective deletion of connective tissue growth factor attenuates experimentally-induced pulmonary fibrosis and pulmonary arterial hypertensionAngela Y Y Tam, Amy L Horwell, Sarah L Trinder, et al.
Arthritis and Rheumatism|April 3, 2008
Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse modelRachel K Hoyles, Korsa Khan, Xu Shiwen, et al.
European Heart Journal. Cardiovascular Imaging|August 19, 2024
Prognostic utility of exercise cardiovascular magnetic resonance in patients with systemic sclerosis-associated pulmonary arterial hypertensionJames T Brown, Ruta Virsinskaite, Tushar Kotecha, et al.
Journal of Scleroderma and Related Disorders|June 24, 2024
Attitudes and barriers to pulmonary arterial hypertension screening in systemic sclerosis patients: A survey of UK-based rheumatologistsMaría Paula Álvarez-Hernández, Yannick Allanore, Ivo Andrade, et al.
Pageof 49